The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells
Open accessAbstract
The proteasome has been successfully targeted for the treatment of multiple myeloma and mantle cell lymphoma; however, in other hematologic malignancies, bortezomib has been less effective as a single agent. Here, we describe effects of NPI-0052, a novel proteasome inhibitor, in leukemia model systems. In cell lines, NPI-0052 inhibits all 3 proteolytic activities associated with the proteasome: chymotrypsin-, trypsin-, and caspase-like. NPI-0052 also induces DNA fragmentation in leukemia lines and in mononuclear cells from a Ph + acute lymphoblastic leukemia (ALL) patient. Caspase-3 activation by NPI-0052 was seen in wild-type Jurkat cells, but was significantly lessened in Fas-associated death domain (FADD)–deficient or caspase-8–deficient counterparts. NPI-0052–induced apoptosis was further probed using caspase-8 inhibitors, which were more protective than caspase-9 inhibitors. N-acetyl cysteine (NAC) also conferred protection against NPI-0052–induced apoptosis, indicating a role for oxidative stress by NPI-0052. In support of the drug's in vitro activities, biweekly treatment with NPI-0052 lessened total white blood cell (WBC) burden over 35 days in leukemic mice. Interestingly, combining NPI-0052 with either MS-275 or valproic acid (VPA) induced greater levels of cell death than the combination of bortezomib with these histone deacetylase inhibitors (HDACi). These effects of NPI-0052, alone and in combination with HDACi, warrant further testing to determine the compound's clinical efficacy in leukemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178
Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis
Yin, X.-M., Wang, K., Gross, A., Zhao, Y., Zinkel, S., Klocke, B., Roth, K. A., & Korsmeyer, S. J. (1999) · Nature · doi:10.1038/23730 · Cited by 1,004
Chauhan, D., Catley, L., Li, G., Podar, K., Hideshima, T., Velankar, M., Mitsiades, C., Mitsiades, N., Yasui, H., Letai, A., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.10.013 · Cited by 694
Self-citationProteasome Inhibition As a Novel Therapeutic Target in Human Cancer
Rajkumar, S. V., Richardson, P. G., Hideshima, T., & Anderson, K. C. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.030 · Cited by 569
Cited by
Targeting the ubiquitin system in cancer therapy
Hoeller, D., & Dikic, I. (2009) · Nature · doi:10.1038/nature07960 · Cited by 599
Aldana-Masangkay, G. I., & Sakamoto, K. M. (2011) · BioMed Research International · doi:10.1155/2011/875824 · Cited by 370
Zhu, K., Dunner, K., & McConkey, D. J. (2010) · Oncogene · doi:10.1038/onc.2009.343 · Cited by 338
Self-citationAntitumor compounds from marine actinomycetes
Olano, C., Méndez, C., & Salas, J. A. (2009) · Marine Drugs · doi:10.3390/md7020210 · Cited by 330
Mechanisms of proteasome inhibitor action and resistance in cancer
McConkey, D. J., & Zhu, K. (2008) · Drug Resistance Updates · doi:10.1016/j.drup.2008.08.002 · Cited by 309
Self-citation
Metadata
- Authors
- Miller, C. P., Ban, K., Dujka, M. E., McConkey, D. J., Munsell, M., Palladino, M., & Chandra, J.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2007-07-01
- Volume
- 110
- Issue
- 1
- Pages
- 267-277
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2010140285
- Cited by
- 204
- References
- 4
- FWCI
- 8.86
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells. https://app.cochat.ai/papers/10.1182/blood-2006-03-013128
- The paper
- Miller, C. P., Ban, K., Dujka, M. E., McConkey, D. J., Munsell, M., Palladino, M., & Chandra, J. (2007). NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells. Blood. https://doi.org/10.1182/blood-2006-03-013128
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.